key: cord-0729867-2xwc3lqb
authors: Funck-Brentano, Christian; Salem, Joe-Elie; Nguyen, Lee S.; Drici, Milou-Daniel; Roden, Dan M.
title: Response to the editorial “COVID-19 in patients with cardiovascular diseases”
date: 2020-04-15
journal: Archives of cardiovascular diseases
DOI: 10.1016/j.acvd.2020.04.001
sha: 05d8cdbb35a06a2703fe6c715f6468b411d31044
doc_id: 729867
cord_uid: 2xwc3lqb

nan

dose, and if possible monitor heart rhythm. Consider stopping therapy if QTc >520 ms is documented.

 Continue to monitor the electrocardiogram as appropriate during treatment (e.g. every other day).

We believe that these simple actions will limit the occurrence of torsade de pointes. If it does occur, the patient can be treated with intravenous magnesium and/or isoproterenol and treatment with the offending drug(s) discontinued.

None.

The authors declare that they have no conflicts of interest concerning this article.

COVID-19 in patients with cardiovascular diseases

In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials

Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

Azithromycin Causes a Novel Proarrhythmic Syndrome

Assessment of temperatureinduced hERG channel blockade variation by drugs

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation

Pitié-Salpêtrière Hospital, F-75013